Rubina Parmar

Statistics

Publications

Citations

1.1K

H-Index

Active since

2013

Affiliations

Alnylam Pharmaceuticals (United States)(Current)

Vanderbilt University

United States Military Academy

Merck & Co., Inc., Rahway, NJ, USA (United States)

Rubina Parmar is an author at Alnylam Pharmaceuticals (United States) specializing in rna interference, molecular biology, and small interfering ribonucleic acids (sirnas).

Publications per year

2013–2022

Publications

Investigating the pharmacodynamic durability of GalNAc–siRNA conjugates

Christopher R. Brown, Swati Gupta, June Qin et al. · Nucleic Acids Research · 2020 · 277 citations · Full text

Life Sciences, Molecular Biology, Pharmacology +17

Selection of GalNAc-conjugated siRNAs with limited off-target-driven rat hepatotoxicity

Maja M. Janas, Mark K. Schlegel, Carole E. Harbison et al. · Nature Communications · 2018 · 266 citations · Full text

Life Sciences, Molecular Biology, Pharmacology +17

5′‐(E)‐Vinylphosphonate: A Stable Phosphate Mimic Can Improve the RNAi Activity of siRNA–GalNAc Conjugates

Rubina Parmar, Jennifer L. S. Willoughby, Jingxuan Liu et al. · ChemBioChem · 2016 · 137 citations

Life Sciences, Molecular Biology, Molecular Genetics +12

siRNA carrying an (E)-vinylphosphonate moiety at the 5΄ end of the guide strand augments gene silencing by enhanced binding to human Argonaute-2

Elad Elkayam, Rubina Parmar, Christopher R. Brown et al. · Nucleic Acids Research · 2016 · 87 citations · Full text

Life Sciences, Molecular Biology, Molecular Genetics +16

Facile Synthesis, Geometry, and 2′-Substituent-Dependent in Vivo Activity of 5′-(E)- and 5′-(Z)-Vinylphosphonate-Modified siRNA Conjugates

Rubina Parmar, Christopher R. Brown, Shigeo Matsuda et al. · Journal of Medicinal Chemistry · 2018 · 56 citations

Pharmacy, Molecular Biology, Pharmaceutics +17

1–5 of 13